When was Famar founded?

Famar was founded in 1949 and raised its 1st funding round 69 years after it was founded.

Where is Famar located?

Famar is headquartered in Athens, Greece.

How many employees does Famar have?

As of Jul 31, 2026, the latest employee count at Famar is 1924.

Is Famar a funded company?

Famar is a funded company, having raised a total of $6.06M across 3 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Dec 12, 2018.

When was the latest funding round of Famar?

Famar's latest funding was a $***** PE round on Sep 04, 2025, with participation from 1 investor.

Where does Famar rank among its competitors?

Famar ranks 2nd amongst 1314 active competitors, of which 49 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Famar, which secured $6.06M in Sep, 2025.

Who are the top competitors of Famar?

Famar's top competitors include Encube Ethicals, Luoxin Pharmaceutical Group and Jubilant Life Sciences. Among them, Famar secured the most recent funding round in September, 2025.

Famar - 2026 Company Profile, Team, Funding & Competitors

Famar is an acquired company based in Athens (Greece), founded in 1949. It operates as a Contract manufacturing and development services provider. Famar has raised $6.06M in funding. The company has 1314 active competitors, including 49 funded and 202 that have exited. Its top competitors include companies like Encube Ethicals, Luoxin Pharmaceutical Group and Jubilant Life Sciences.

Company Details

Farmar provides contract manufacturing and development services for pharmaceutical and health & beauty industry. It provides services such as product transfers and industrialization, product development, quality assurance, technical R&D, manufacturing, analytical method validation, packaging, and logistics.

Website: www.famar-group.com/
Email ID: *****@famar.eu
Phone Number: +30 **********

Key Metrics

Founded Year

1949

Location

Athens, Greece

Stage

Acquired

Total Funding

$6.06M in 3 rounds

Latest Funding Round

PE, Sep 04, 2025, $*****

Investors

Metric Capital & 2 more

Ranked

2^nd among 1314 active competitors

Employee Count

1,924 as on Jul 31, 2026

Similar Companies

Encube Ethicals & 81 more

Exit Details

Acquired by MidEuropa (Jul 22, 2024)

View Famar's full profile

Famar got acquired by MidEuropa on Jul 22, 2024.

Click here to take a look at Famar's acquisition in detail

Famar has raised a total funding of $6.06M over 3 rounds. Its first funding round was on Dec 12, 2018. Its latest funding round was a PE round on Sep 04, 2025 for $*****. 1 investor participated in its latest round. Famar has 3 institutional investors.

Here is the list of recent funding rounds of Famar:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 04, 2025	4209110	PE	6570643	9662370	6215211	3630839
Oct 21, 2024	2190369	Conventional Debt	9370365	3540185	2680869	EBRD
Dec 12, 2018	1302341	Conventional Debt	3706999	9303357	4711223	Pillarstone

Access funding benchmarks and valuations. Sign up today!

View details of Famar's funding rounds and investors

Famar's employee count trend

Famar has 1,924 employees as of Jul 26. Here is Famar's employee count trend over the years:

Uncover Famar's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Famar include Encube Ethicals, Luoxin Pharmaceutical Group and Jubilant Life Sciences. Here is the list of Top 10 competitors of Famar, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Encube Ethicals 1998, Mumbai (India), Series D	Company offering contract development and manufacturing services for topical semisolid formulations	$65.5M	Quadria Capital, GII & 3 others	64/100
2nd	Famar 1949, Athens (Greece), Acquired	Contract manufacturing and development services provider	$6.06M	Metric Capital, EBRD & 1 others	63/100
3rd	Luoxin Pharmaceutical Group 2006, Linyi (China), Acquired	Developer and manufacturer of pharmaceutical products	$301M	Ennovation Ventures, Yuanchuang Duoying Investment Group ... Read more	61/100
4th	Jubilant Life Sciences 1978, Noida (India), Public	Company offering a suite of R&D and manufacturing services for small molecules and generics	-	Samena Capital, General Atlantic & 1 others	59/100
5th	Akums 2004, Delhi (India), Public	CDMO focusing on spectrum of dosage forms and therapeutic segments	$70M	Quadria Capital & 5 others	58/100
6th	Nivagen Pharmaceuticals 2009, Sacramento (United States), Acquired	Developer and contract manufacturer of generic drugs, tablets, capsules, ointment and solution	$31M	Telegraph Hill Partners, BizCap & 1 others	57/100
7th	Crown Laboratories 2000, Johnson City (United States), Acquired	Manufacturer of OTC, prescription, skin care and oral care products	-	Greenspring Associates, Montreux Equity Partners ... & 2 others	55/100
8th	Nectar Lifesciences 1995, Chandigarh (India), Public	Manufacturer of cephalosporin APIs and generic formulations	$46.9M	Vedanta Capital, NSR Partners & 1 others	55/100
9th	Suzhou Ze Jing Biological Pharmaceutical 2009, Suzhou (China), Series B	Company developing small molecules & eukaryotic cell based recombinant protein drugs	$61.9M	Shenzhen Capital Group, Share Capital & 8 others	54/100
10th	Recipharm 1995, Jordbro (Sweden), Acquired	Contract services for pharmaceutical development and manufacturing	-	CPP Investments, Ampersand Capital	54/100